Clinical trials
Alveolar Soft Part Sarcoma clinical trials
Below are recruiting alveolar soft part sarcoma clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07615049RecruitingPhase 3
Shorter versus standard radiation for soft tissue sarcoma
This trial compares a shorter course of radiation therapy with the standard longer course for people with soft tissue sarcoma in an arm or leg. The goal is to see if the shorter course works just as well and may be more convenient.
Birmingham, AlabamaAges 18 years+ - NCT07548177RecruitingPhase 2
Combination drug study for advanced soft tissue sarcoma
This study tests two cancer drugs (benmelstobart and anlotinib) together to treat alveolar soft part sarcoma, a rare soft tissue cancer that has spread or cannot be surgically removed. The drugs work by boosting the immune system and blocking tumor blood vessel growth.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07297667RecruitingPhase 1
CAR T-cell therapy for certain advanced solid tumors
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
Calgary, AlbertaAges 15 years+ - NCT06625190RecruitingPhase 1/Phase 2
Half-matched transplant with zoledronic acid for resistant solid tumors
This trial tests a new approach using a special type of transplant (with cells from a half-matched family donor) plus a drug called zoledronic acid. It is for children and young adults with certain solid tumors that have not responded to standard treatments.
Gainesville, FloridaAges 6 months–25 years - NCT06066138RecruitingPhase 1
Trial: Adjusting Atezolizumab Dose Based on Drug Levels in Blood
This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).
Bethesda, MarylandAges 18–120 - NCT05333458RecruitingPhase 2
Atezolizumab plus selinexor for advanced alveolar soft tissue sarcoma
This Phase 2 trial tests whether combining atezolizumab with selinexor can slow or shrink advanced alveolar soft part sarcoma (ASPS) in people age 12 and older. It may help by improving the immune system’s ability to fight the cancer and stopping cancer cell growth signals.
Los Angeles, CaliforniaAges 12 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT04332874RecruitingPhase 2
Pembrolizumab with local limb chemotherapy for sarcoma in arms or legs
This trial tests whether giving pembrolizumab along with chemotherapy delivered directly into an arm or leg (isolated limb infusion) can shrink sarcoma tumors. It is for people with advanced or metastatic sarcoma in an arm or leg who can safely have this local treatment.
Basking Ridge, New JerseyAges 12 years+ - NCT03967834Recruiting
Study of immune features in rare soft tissue sarcoma
This study looks at immune system “fingerprints” using tumor tissue from people with rare soft tissue sarcoma. It may help researchers understand what drives these cancers and guide future treatments.
BesançonAges 18 years+ - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Phoenix, ArizonaAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT07032285RecruitingPhase 2
Cirtuvivint for advanced soft-tissue sarcomas
This trial tests a new drug called Cirtuvivint for people with certain advanced soft-tissue sarcomas that have grown recently. It aims to see if the drug can stop or slow tumor growth.
Madrid, MadridAges 16–70 - NCT04307277RecruitingPhase 3
Chemotherapy before and after surgery for high-risk soft tissue sarcoma
This trial tests whether giving chemotherapy both before and after surgery helps people with high-risk soft tissue sarcoma live longer and prevents the cancer from coming back. It aims to see if this treatment plan is more effective than surgery alone.
BesançonAges 18 years+ - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT06644287Recruiting
PET scan to track immunotherapy response in advanced sarcoma
This trial uses a special PET scan called 68Ga-grazytracer to see how well your soft tissue sarcoma responds to immunotherapy treatment. It may help doctors understand if the treatment is working.
Shanghai, Shanghai MunicipalityAges 6–80 - NCT03805022RecruitingPhase 3
Extra chemotherapy around surgery for high-risk soft-tissue sarcoma
This trial tests whether giving stronger chemotherapy before and/or after surgery helps people with high-risk, resectable soft-tissue sarcoma. It aims to lower the chance the cancer comes back by improving treatment around the time of the operation.
BordeauxAges 18 years+ - NCT02789384Recruiting
Study of tumor markers to predict chemotherapy benefit in sarcoma
This study looks at stored tumor tissue (or takes a new biopsy) to measure specific tumor markers. Researchers want to see whether these markers match how well chemotherapy works before surgery for soft-tissue sarcoma.
BordeauxAges 18 years+ - NCT06981637RecruitingPhase 2
PLD vs. observation for advanced soft tissue sarcoma
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Kaohsiung CityAges 18 years+ - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT05634369RecruitingPhase 1/Phase 2
NK cell and chemotherapy trial for relapsed soft tissue sarcoma
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
South Birmingham, AlabamaAges 2–40 - NCT05597917RecruitingPhase 3
Test drug trabectedin for advanced soft-tissue sarcoma
This Phase 3 trial tests trabectedin (in tTF-NGR study) for people with advanced or metastatic soft-tissue sarcoma whose first treatment with anthracycline drugs didn’t work (or can’t be used). It aims to see if this approach works better than the study comparison treatment, using tumor response and other safety outcomes.
Bad SaarowAges 18–75 - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+
Hear when a new Alveolar Soft Part Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alveolar soft part sarcoma?
- Yes. Clin2 currently lists 22 recruiting alveolar soft part sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alveolar soft part sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alveolar soft part sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.